Phase 1 trials of molecular targeted therapies: Are we evaluating toxicities properly?

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1443-1445

  Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB;

ACUTE TOXICITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER THERAPY; CHRONIC TOXICITY; DISEASE SEVERITY; DOSE LIMITING TOXICITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SCREENING; DRUG TOXICITY; EDITORIAL; HUMAN; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TOXICITY TESTING;

EID: 79958774831     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.009     Document Type: Note

References (5)

1. E. Horstmann Risks and benefits of phase 1 oncology trials, 1991 through 2002 N Engl J Med 352 9 2005 895 904 (Pubitemid 40300298)
2. Postel-Vinay S, et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 2011, doi:10.1200/JCO.2010.31.9236.
3. M.B. Atkins Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 5 2004 909 918 (Pubitemid 41103603)
4. S.G. Arbuck Workshop on phase I study design Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996 Ann Oncol 7 6 1996 567 573 (Pubitemid 26285635)
5. Le Tourneau C, et al. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer, this issue.